Dylann Cohn-Emery | Authors


FDA Recommends Including Patients on Trials Regardless of Prior Therapies in the Non-Curative Setting

July 14, 2021

In a draft guidance for clinical investigators and sponsors, the FDA made recommendations on how to expand eligibility to patients with incurable cancer through clinical trial designs of investigational cancer drugs and biological products.

HER2+ Status at Diagnosis in Patients With mBC Shows More Favorable PFS Than HER2-Negative Status

July 12, 2021

A prospective analysis demonstrated a trend toward worse prognosis for patients with metastatic breast cancer who were initially HER2 negative and switched to HER2 positive treated with HER2-directed therapies compared with those who were HER2 positive at diagnosis.

High BMI Negatively Impacts Survival Outcomes With Osimertinib in EGFR+ NSCLC

July 05, 2021

In a retrospective analysis of patients with advanced non–small cell lung cancer and EGFR mutations treated with osimertinib, investigators found that body mass index of 25 kg/mq2 or more had a negative impact on survival outcomes.

Phase 2 Trials Currently Filling Unmet Needs in Advanced HCC

July 01, 2021

A phase 2 trial of tislelizumab and another trial of Tumor Treating Fields accompanied by sorafenib are filling unmet needs in advanced hepatocellular carcinoma, although more data are still needed in this space.